Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Biovica International AB (publ)
  6. Summary
    BIOVIC B   SE0008613731

BIOVICA INTERNATIONAL AB (PUBL)

(BIOVIC B)
  Report
Delayed Quote. Delayed Nasdaq Stockholm - 06/17 11:29:58 am
47.7 SEK   +1.27%
02:00aBIOVICA INTERNATIONALá : Year-end Report February-April 2020/2021
AQ
06/11BIOVICA INTERNATIONALá : - Premium potential
AQ
05/22BIOVICA INTERNATIONALá : Capital Markets Day invitation June 9
AQ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Stockholm
06/11/2021 06/14/2021 06/15/2021 06/16/2021 06/17/2021 Date
44.7(c) 46.7(c) 47(c) 47.1(c) 47.7 Last
378 993 157 958 81 182 68 275 111 913 Volume
+10.51% +4.47% +0.64% +0.21% +1.27% Change
More quotes
Financials
Sales 2021 3,00 M 0,35 M 0,35 M
Net income 2021 -40,0 M -4,72 M -4,72 M
Net cash position 2021 133 M 15,7 M 15,7 M
P/E ratio 2021 -33,2x
Yield 2021 -
Sales 2022 39,0 M 4,60 M 4,60 M
Net income 2022 -28,0 M -3,31 M -3,31 M
Net cash position 2022 110 M 13,0 M 13,0 M
P/E ratio 2022 -47,6x
Yield 2022 -
Capitalization 1 339 M 160 M 158 M
EV / Sales 2021 402x
EV / Sales 2022 31,5x
Nbr of Employees 20
Free-Float 41,9%
More Financials
Company
Biovica International AB is a Sweden-based biotechnology company. It develops and commercializes blood-based biomarker assays for the monitoring of cancer therapies and for prediction of patient outcome. The Company has focus on breast cancer and its main product DiviTum is a blood-based test, which measures the activity of the enzyme thymidine kinase-1 (TK) in blood serum or cell cultures. The Company collaborates... 
More about the company
Ratings of Biovica International AB (publ)
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about BIOVICA INTERNATIONAL AB (PUBL)
02:00aBIOVICA INTERNATIONALá : Year-end Report February-April 2020/2021
AQ
06/11BIOVICA INTERNATIONALá : - Premium potential
AQ
05/22BIOVICA INTERNATIONALá : Capital Markets Day invitation June 9
AQ
05/20BIOVICA INTERNATIONALá : DiviTumTKa shows strong capabilities in malignant melan..
AQ
04/29BIOVICA INTERNATIONALá : strengthens the management team
AQ
04/23BIOVICA INTERNATIONALá : DiviTum«TKa budget impact model results show potential ..
AQ
03/18BIOVICA INTERNATIONALá : Q3 Interim report November-January 2020/2021
AQ
03/11BIOVICA INTERNATIONALá : DiviTumTKa prognostic for long-term outcome
AQ
02/26BIOVICA INTERNATIONALá : Nomination Committee for Biovica for the 2021 Annual Ge..
AQ
01/29BIOVICA INTERNATIONALá : FDA resumes review of DiviTum«TKa submission
AQ
01/18BIOVICA INTERNATIONALá : DiviTum«TKa in early treatment resistance trial
AQ
01/16BIOVICA INTERNATIONALá : FDA resource reallocation continues to impact DiviTum«T..
AQ
01/12BIOVICA INTERNATIONALá : CEO and main shareholder lends shares for redemption of..
AQ
2020BIOVICA INTERNATIONALá : Q2 Interim Report August-October 2020/2021
AQ
2020BIOVICA INTERNATIONALá : DiviTum«TKa included in new UK breast cancer study
AQ
More news
News in other languages on BIOVICA INTERNATIONAL AB (PUBL)

- No features available -

More news
Chart BIOVICA INTERNATIONAL AB (PUBL)
Duration : Period :
Biovica International AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 2
Average target price
Last Close Price 47,10 
Spread / Highest target -
Spread / Average Target -
Spread / Lowest Target -
EPS Revisions
Managers and Directors
NameTitle
Anders Rylander Chief Executive Officer & Director
Cecilia Driving CFO, Head-Human Resource, IR & EVP
Lars Erik Holmqvist Chairman
Mattias Bergqvist Director-Clinical Development
Otti Bengtsson Gref Director-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
BIOVICA INTERNATIONAL AB (PUBL)-8.01%160
EXACT SCIENCES CORPORATION-9.14%20 651
GUARDANT HEALTH, INC.-9.07%11 850
BGI GENOMICS CO., LTD.-10.15%7 401
INVITAE CORPORATION-27.94%6 021
ADAPTIVE BIOTECHNOLOGIES CORPORATION-35.80%5 326